Nuvectis Pharma (NVCT) announced a new publication from the laboratory of Prof. Ruth Keri demonstrating that the combination of NXP900 and osimertinib was superior to single agent osimertinib in vivo in a model of Epidermal Growth Factor Receptor mutated non-small cell lung cancer, and led to decreased cell proliferation and increased apoptosis in vitro. The data reported in this new publication further supports the mechanistic rationale for the combination of NXP900 and EGFR inhibitors in EGFR-mutated tumors, and further validates the data previously published by the research team at Astra Zeneca which demonstrated that the addition of NXP900 to osimertinib reverses resistance to osimertinib in osimertinib resistant cell lines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCT:
- Nuvectis Pharma Reports 2024 Financial Results and Progress
- Nuvectis Pharma initiated with a Buy at Lucid Capital
- Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position
- Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright
- Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year
Questions or Comments about the article? Write to editor@tipranks.com